These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10517371)

  • 21. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
    Knecht W; Löffler M
    Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assay of Escherichia coli dihydroorotase with enantiomeric substrate: practical preparation of carbamyl L-aspartate and high-performance liquid chromatography analysis of catalysis product.
    Daniel R; Kokel B; Caminade E; Martel A; Le Goffic F
    Anal Biochem; 1996 Aug; 239(2):130-5. PubMed ID: 8811890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of experimental autoimmune neuritis by leflunomide.
    Korn T; Toyka K; Hartung HP; Jung S
    Brain; 2001 Sep; 124(Pt 9):1791-802. PubMed ID: 11522581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response of the pyrimidine pathway of Escherichia coli K 12 to exogenous adenine and uracil.
    Christopherson RI; Finch LR
    Eur J Biochem; 1978 Oct; 90(2):347-58. PubMed ID: 361403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-HIV-1 activity of leflunomide: a comparison with mycophenolic acid and hydroxyurea.
    Schläpfer E; Fischer M; Ott P; Speck RF
    AIDS; 2003 Jul; 17(11):1613-20. PubMed ID: 12853743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases.
    Mangold U; Dax CI; Saar K; Schwab W; Kirschbaum B; Müllner S
    Eur J Biochem; 1999 Dec; 266(3):1184-91. PubMed ID: 10583416
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An overall radioassay for the first three reactions of de novo pyrimidine biosynthesis.
    Christopherson RI; Yu ML; Jones ME
    Anal Biochem; 1981 Mar; 111(2):240-9. PubMed ID: 6113788
    [No Abstract]   [Full Text] [Related]  

  • 28. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation.
    Dimitrova P; Skapenko A; Herrmann ML; Schleyerbach R; Kalden JR; Schulze-Koops H
    J Immunol; 2002 Sep; 169(6):3392-9. PubMed ID: 12218161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substitutions in the aspartate transcarbamoylase domain of hamster CAD disrupt oligomeric structure.
    Qiu Y; Davidson JN
    Proc Natl Acad Sci U S A; 2000 Jan; 97(1):97-102. PubMed ID: 10618377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
    Karle JM; Cowan KH; Chisena CA; Cysyk RL
    Mol Pharmacol; 1986 Aug; 30(2):136-41. PubMed ID: 2874477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leflunomide: mode of action in the treatment of rheumatoid arthritis.
    Breedveld FC; Dayer JM
    Ann Rheum Dis; 2000 Nov; 59(11):841-9. PubMed ID: 11053058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In situ properties of Helicobacter pylori aspartate carbamoyltransferase.
    Burns BP; Mendz GL; Hazell SL
    Arch Biochem Biophys; 1997 Nov; 347(1):119-25. PubMed ID: 9344472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of leflunomide in tablets by high performance liquid chromatography.
    Yeniceli D; Dogrukol-Ak D; Tuncel M
    J Pharm Biomed Anal; 2006 Jan; 40(1):197-201. PubMed ID: 16112831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leflunomide interferes with pyrimidine nucleotide biosynthesis.
    Cherwinski HM; Byars N; Ballaron SJ; Nakano GM; Young JM; Ransom JT
    Inflamm Res; 1995 Aug; 44(8):317-22. PubMed ID: 8581517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of ammonium ions on hepatic de novo pyrimidine biosynthesis.
    Monks A; Chisena CA; Cysyk RL
    Arch Biochem Biophys; 1985 Jan; 236(1):1-10. PubMed ID: 2981502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro.
    Chong AS; Rezai K; Gebel HM; Finnegan A; Foster P; Xu X; Williams JW
    Transplantation; 1996 Jan; 61(1):140-5. PubMed ID: 8560553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pyrimidine nucleosides enhance the efficacy of inhibitors of pyrimidine biosynthesis in cultured hepatocellular carcinoma cells.
    Jacobsen LB; Putnam JE; Sawick DP; Cassady JM; Morré DJ
    Life Sci; 1988; 42(8):913-8. PubMed ID: 3343891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of new immunosuppressants.
    Halloran PF
    Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine.
    Pinschewer DD; Ochsenbein AF; Fehr T; Zinkernagel RM
    Transplantation; 2001 Aug; 72(4):712-9. PubMed ID: 11544436
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.